Cassava Sciences Inc vs Motorola Solutions Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Motorola Solutions Inc trades at $412.53 (market cap $67.59B). The key difference: Motorola Solutions Inc is far larger — about 1271.9× Cassava Sciences Inc's market cap, and Motorola Solutions Inc pays a 1.19% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MSI | |
|---|---|---|
Market Cap | $53.14M | $67.59B |
Sector | Health | Technology |
52-Week High | $4.64 | $490.30 |
52-Week Low | $1.09 | $363.83 |
Enterprise Value | -$33.43M | $76.29B |
Dividend Yield | — | 1.19% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Motorola Solutions (MSI) trades at $411.88, down 0.44% on the day, with a bearish technical signal but strong fundamentals. The company reported Q1 2026 EPS of $3.37, beating estimates, and maintains robust profitability with a net margin of 17.61% and ROE of 99.88%. Recent developments include the $1.5 billion acquisition of D-Fend Solutions and expansion of AI tools for public safety, signaling growth in mission-critical ecosystems.
Outlook is positive driven by AI innovation and a $15.7 billion backlog, though high valuation multiples (P/E 32.84) and significant debt pose risks. Analysts are bullish with a consensus price target of $512.33, representing 24% upside, but investors should monitor integration of acquisitions and competitive pressures from peers like Axon.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →